Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as MNTX tablet (Formulation 1), SC MNTX, Methylnaltrexone, MOA-728
MNTX · 20 trials · 16 indications
RFBM was defined as a bowel movement without laxative use within 24 hours prior to bowel movement.
There were 2 co-primary endpoints for this study. This measurement is the first of the 2 co-primary endpoints. This endpoint measures the percentage of patients who had an RFBM within 4 hours after the first dose of test article during the double-blind period; data are expressed as percentages of patients for the MNTX and placebo groups. To qualify as rescue free, the bowel movement could not occur within 6 hours after a rectal intervention (ie, rectal suppository, enema, manual disimpaction). Note that efficacy results (primary and secondary outcomes) are presented for the double-blind period only. Therefore, no efficacy results are presented for the open-label period.
This measurement is the second of the 2 co-primary endpoints. This endpoint measures the percentage of patients who had an RFBM within 4 hours after each dose of test article during the double-blind period; data are expressed as percentages of patients by dose (first, second, third, fourth, etc.) for the MNTX and placebo groups. The definition of RFBM is described above (see first co-primary endpoint).
Time to first bowel movement was measured from the end of surgery (defined as the time when the last skin suture or staple was placed in the participant). Time of the first bowel movement was recorded on the electronic case report form (eCRF). The first bowel movement was defined as a normal stool for a postoperative participant based on the clinical judgment of the investigator or designee. Analysis was performed by Kaplan-Meier estimate. Participants who had a bowel movement but were readmitted to the hospital within 1 week after discharge with a diagnosis of postoperative ileus (POI) were considered censored at the time of the first bowel movement as if the bowel movement had not occurred.
To provide access to treatment with MNTX, administered SC, to patients who completed Progenics' Protocol MNTX 302
To determine the efficacy of a single dose of SC MNTX compared with placebo in inducing laxation within 4 hours. To determine the efficacy of SC MNTX every other day over a 1-week treatment period in relieving OIC in patients with AMI.
The primary objective is to determine the efficacy of SC MNTX administered as a single dose, dose 1 and dose 2 compared with placebo in inducing laxation in 4 hours in patients with advanced medical illness and OIC who are poorly responsive to laxatives.
To assess the activity of parenterally administered MNTX compared with placebo in shortening the duration of or preventing post-operative ileus in patients who have undergone segmental colectomies.
To access the efficacy of various fixed unit doses of MNTX SC in patients with advanced medical illnesses and poorly controlled opioid-induced constipation.
To compare the PK of MNTX administered subcutaneously as a single dose in patients with impaired renal function with the PK of MNTX administered to healthy subjects.
To evaluate the pharmacokinetics of MNTX administered subcutaneously as a single dose in individuals with impaired liver and hepatic function compared to healthy controls.
| Arm | Type | Description |
|---|---|---|
| MNTX 150 mg | EXPERIMENTAL | Participants will receive methylnaltrexone (MNTX) 150 milligrams (mg) (1 tablet of MNTX 150 mg and 2 matching placebo tablets) orally once daily (QD) for 28 days (4 weeks), then MNTX tablets at a dose as needed (PRN) for remaining 56 days (8 weeks). |
| MNTX 300 mg | EXPERIMENTAL | Participants will receive MNTX 300 mg (2 tablets of MNTX 150 mg each and 1 matching placebo tablet) orally QD for 28 days (4 weeks), then MNTX tablets at a dose PRN for remaining 56 days (8 weeks). |
| MNTX 450 mg | EXPERIMENTAL | Participants will receive MNTX 450 mg (3 tablets of MNTX 150 mg each) orally QD for 28 days (4 weeks), then MNTX tablets at a dose PRN for remaining 56 days (8 weeks). |
| Placebo | PLACEBO_COMPARATOR | Participants will receive 3 tablets of placebo matched to MNTX orally QD for 84 days (12 weeks). |
| Methylnaltrexone double-blind | EXPERIMENTAL | Methylnaltrexone once every other day. |
| Methylnaltrexone open-label | OTHER | Subjects who completed the double-blind period had the option to receive methylnaltrexone once every other day during a 12-week, open-label extension period. |
| MOA-728 12 mg | EXPERIMENTAL | Participants will receive methylnaltrexone (MOA-728) 12 mg as an IV infusion over approximately 20 minutes for approximately every 6 hours for a total of 4 doses in 24-hour period. The first dose of study drug will be administered within approximately 90 minutes after completion of the surgical procedure (defined as the time when the last skin suture or staple is placed in the participant). Dose administration will be continued for a maximum of 10 days. |
| MOA-728 24 mg | EXPERIMENTAL | Participants will receive MOA-728 24 mg as an IV infusion over approximately 20 minutes for approximately every 6 hours for a total of 4 doses in 24-hour period. The first dose of study drug will be administered within approximately 90 minutes after completion of the surgical procedure (defined as the time when the last skin suture or staple is placed in the participant). Dose administration will be continued for a maximum of 10 days. |
| MNTX 12 mg | EXPERIMENTAL | Participants will receive methylnaltrexone (MNTX) 12 milligrams (mg) as an intravenous (IV) infusion over approximately 20 minutes for every 6 hours until one of the following occurs: 1) 24 hours elapsed after the first bowel movement and the participant was tolerating clear liquids, 2) the participant was discharged from the hospital, or 3) a maximum of 10 days elapsed. The first dose of study drug will be administered within the first 90 minutes after the end of surgery (defined as the time when the last skin suture or staple is placed in the participant). |
| MNTX 24 mg | EXPERIMENTAL | Participants will receive MNTX 24 mg as an IV infusion over approximately 20 minutes for every 6 hours until one of the following occurs: 1) 24 hours elapsed after the first bowel movement and the participant was tolerating clear liquids, 2) the participant was discharged from the hospital, or 3) a maximum of 10 days elapsed. The first dose of study drug will be administered within the first 90 minutes after the end of surgery (defined as the time when the last skin suture or staple is placed in the participant). |
| Arm 1 | EXPERIMENTAL | - |
| Arm 2 | PLACEBO_COMPARATOR | - |
| Arm 3 | PLACEBO_COMPARATOR | - |
| 150 mg | EXPERIMENTAL | MOA-728 |
| 300 mg | EXPERIMENTAL | MOA-728 |
| 450 mg | EXPERIMENTAL | MOA-728 |
| 600 mg | EXPERIMENTAL | MOA-728 |
| Name | Type | Description |
|---|---|---|
| Methylnaltrexone | DRUG | Methylnaltrexone will be administered as per the dose and schedule specified in the respective arms. |
| Placebo | DRUG | Placebo matching to methylnaltrexone will be administered as per the schedule specified in the respective arms. |
| MOA-728 | DRUG | MOA-728 will be administered per the dose and schedule specified in the arm. |
| Methylnaltrexone (MOA-728) | DRUG | - |
| SC Methylnaltrexone | DRUG | - |
| SC Placebo | DRUG | - |
| SC Methylnaltrexone (MNTX) | DRUG | - |
| IV Methylnaltrexone (MNTX) | DRUG | - |
| SC MNTX | DRUG | Dose 1 |
| Methylnaltrexone (MNTX) | DRUG | - |
Key Inclusion Criteria: 1. History of chronic non-malignant pain (originating from a non-malignant source) with condition(s) underlying the chronic pain of greater than or equal to (≥) 2 months' duration before the screening visit. 2. Taking oral, transdermal, intravenous (IV), or subcutaneous (SC)...
MNTX is being developed for bowel dysfunction, specifically opioid-induced bowel dysfunction. It is a small molecule therapeutic candidate studied in adults aged 18 years and older. Development is at Phase 2, and the program is led by Bausch Health Companies Inc. under the ticker BHC.
MNTX is developed by Bausch Health Companies Inc., which trades under the ticker BHC. The company is the sponsor behind the clinical program evaluating MNTX in bowel dysfunction, including the Phase 2 study conducted in the United States.
MNTX is in Phase 2 clinical development for bowel dysfunction. It is an investigational small molecule and has not been approved by the FDA for this use. One Phase 2 trial has been completed, and no active trials are currently listed for the program.
MNTX has been studied in one completed Phase 2 trial, NCT01367574, titled Methylnaltrexone in Patients With Opioid-Induced Bowel Dysfunction. The randomized, controlled study enrolled 39 adults aged 18 years and older in the United States and included both sexes.
Yes. MNTX is also known as MNTX tablet (Formulation 1) and SC MNTX. These names refer to the same investigational small molecule being developed by Bausch Health Companies Inc. for bowel dysfunction, including opioid-induced bowel dysfunction.